# A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

> **NCT07538804** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Avistone Biotechnology Co., Ltd.** · enrollment: 294 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** ANS02

## Key facts

- **NCT ID:** NCT07538804
- **Lead sponsor:** Avistone Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-09
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07538804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07538804, "A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07538804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*